Home Bratislava Medical Journal 2023 Bratislava Medical Journal Vol.124, No.8, p.615–621, 2023

Journal info


 


Published Monthly, in English
Founded: 1919
ISSN 0006-9248
(E)ISSN 1336-0345

Impact factor 1.564

 

Aims and Scope
Editorial Info
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Bratislava Medical Journal Vol.124, No.8, p.615–621, 2023

Title: Experience of using genetically engineered biological drugs in children with a systemic form of JIA in the Karaganda region
Author: Tattigul KENZHETAEVA, Zamira KENZHETAYEVA, Ainur MELDEBEKOVA, Lazat BATYRBEKOVA, Abi ABLASANO, Gaukhar ZHUMANOVA
Abstract: Despite all the achievements of science and medicine, juvenile idiopathic arthritis today remains one of the main childhood diseases that lead to severe irreversible consequences. This, in turn, makes it urgent to search for effective drugs for the treatment of juvenile idiopathic arthritis, of which interleukin 1 (anakinra) and interleukin 6 (tocilizumab) inhibitors are becoming increasingly popular.
AIM: to analyse the efficacy of genetically engineered biological drugs, namely anakinra and tocilizumab in children with systemic juvenile idiopathic arthritis among patients of the Karaganda region. The study involved 176 patients aged 4–17 years with a diagnosis of systemic juvenile idiopathic arthritis and with resistance to methotrexate for 3 months. Among all patients, 64 children received injections of anakinra, and 63 received tocilizumab in standard doses. The control group consisted of 50 patients of the same age category. Assessment of the efficacy of treatment was conducted at 2, 4, 8, 16, 24, and 48 weeks using ACR Pediatric criteria. The clinical effect of both drugs was detected as early as the second week after the start of therapy. At week 12 of the study in the tocilizumab group, the efficacy of treatment for ACR Pediatric 30, 50, and 70 reached 82 %, 71 %, and 69 %, and in the anakinra group – 89 %, 81 %, and 80 % respectively, while in the control group ACR Pediatric 30 after 12 weeks of treatment was achieved in 21 % of patients, ACR Pediatric 50 – in 12 %, and ACR Pediatric 70 – in 9 % (p
Keywords: systemic arthritis, polyarthritis, tocilizumab, anakinra, genetically engineered biological drugs
Published online: 16-May-2023
Year: 2023, Volume: 124, Issue: 8 Page From: 615, Page To: 621
doi:10.4149/BLL_2023_096


download file


© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.